Cargando…

Anti‐CD22 and anti‐CD79b antibody‐drug conjugates preferentially target proliferating B cells

BACKGROUND AND PURPOSE: CD22 and CD79b are cell‐surface receptors expressed on B‐cell‐derived malignancies such as non‐Hodgkin's lymphoma (NHL). An anti‐mitotic agent, monomethyl auristatin E, was conjugated to anti‐CD22 and anti‐CD79b antibodies to develop target‐specific therapies for NHL. Th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fuh, Franklin K, Looney, Caroline, Li, Dongwei, Poon, Kirsten A, Dere, Randall C, Danilenko, Dimitry M, McBride, Jacqueline, Reed, Chae, Chung, Shan, Zheng, Bing, Mathews, William Rodney, Polson, Andrew, Prabhu, Saileta, Williams, Marna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368047/ https://www.ncbi.nlm.nih.gov/pubmed/28009435 http://dx.doi.org/10.1111/bph.13697

Ejemplares similares

Evaluation and use of an anti‐cynomolgus monkey CD79b surrogate antibody–drug conjugate to enable clinical development of polatuzumab vedotin
por: Li, Dongwei, et al.
Publicado: (2019)

Nonclinical Pharmacokinetics and Pharmacodynamics Characterization of Anti-CD79b/CD3 T Cell-Dependent Bispecific Antibody Using a Surrogate Molecule: A Potential Therapeutic Agent for B Cell Malignancies
por: Yadav, Rajbharan, et al.
Publicado: (2022)

Anti-CD79B Antibody–Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study
por: Herrera, Alex F., et al.
Publicado: (2022)

Preclinical Evidence for the Efficacy of CD79b Immunotherapy in B-cell Precursor Acute Lymphoblastic Leukemia
por: Lenk, Lennart, et al.
Publicado: (2022)

Continuous signaling of CD79b and CD19 is required for the fitness of Burkitt lymphoma B cells
por: He, Xiaocui, et al.
Publicado: (2018)

Single cell-produced and in vitro-assembled anti-FcRH5/CD3 T-cell dependent bispecific antibodies have similar in vitro and in vivo properties
por: Ovacik, Ayse Meric, et al.
Publicado: (2018)

Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas
por: Chu, Fuliang, et al.
Publicado: (2023)

United we stand: Double targeting of CD79B and CD20 in diffuse large B‐cell lymphoma
por: Tarantelli, Chiara, et al.
Publicado: (2022)

CD79B and MYD88 Mutations in Splenic Marginal Zone Lymphoma
por: Trøen, Gunhild, et al.
Publicado: (2013)

Human CD79b(+) neutrophils in the blood are associated with early-stage melanoma
por: Meyer, Melissa A., et al.
Publicado: (2023)

P1237: PRELIMINARY RESULTS OF A PHASE Ⅱ STUDY OF ZANUBRUTINIB COMBINED WITH IMMUNOCHEMOTHERAPY IN PATIENTS WITH CD79A/CD79B-MUTANT DIFFUSE LARGE B-CELL LYMPHOMA
por: Yan, Z., et al.
Publicado: (2022)

Immunodominant Tuberculosis CD8 Antigens Preferentially Restricted by HLA-B
por: Lewinsohn, Deborah A, et al.
Publicado: (2007)

Empty conformers of HLA-B preferentially bind CD8 and regulate CD8(+) T cell function
por: Geng, Jie, et al.
Publicado: (2018)

Possible role of CD22, CD79b and CD20 expression in distinguishing small lymphocytic lymphoma from chronic lymphocytic leukemia
por: Jovanovic, Danijela, et al.
Publicado: (2014)

An open-label safety and efficacy study of an anti-CD20 antibody (rituximab, Rituxan) for anti-B-cell therapy in the treatment of systemic lupus erythematosus
por: Eisenberg, RA, et al.
Publicado: (2004)

Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations
por: Kersten, M J, et al.
Publicado: (2014)

Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice
por: Visco, Carlo, et al.
Publicado: (2020)

Circulating Type-1 Anti-Tumor CD4(+) T Cells are Preferentially Pro-Apoptotic in Cancer Patients
por: Wesa, Amy K., et al.
Publicado: (2014)

Paradox of Protection: Preferential Recognition of CD4-induced Epitopes by Anti-HIV-1 ADCC Antibodies
por: Parsons, Matthew S., et al.
Publicado: (2015)

Preferential expansion of CD8(+) CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL
por: Talleur, Aimee C., et al.
Publicado: (2022)

PIM1 and CD79B Mutation Status Impacts the Outcome of Primary Diffuse Large B-Cell Lymphoma of the CNS
por: Zhou, Jihao, et al.
Publicado: (2022)

Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti‐β7 integrin therapy for inflammatory bowel disease
por: Tang, M. T., et al.
Publicado: (2018)

A novel ten-gene prognostic signature for cervical cancer based on CD79B-related immunomodulators
por: Pu, Dan, et al.
Publicado: (2022)

Treatment of B cells malignancies with anti-CD19 CAR+, TCR-, CD52- allogeneic T cells
por: Mannioui, Cécile Schiffer, et al.
Publicado: (2013)

CD40-CD40 ligand interactions are critical in T-B cooperation but not for other anti-viral CD4+ T cell functions
Publicado: (1996)

Anti-CD20 B Cell Treatment for Relapsing Multiple Sclerosis
por: Roach, Charles A., et al.
Publicado: (2021)

Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma
por: Wei, Jia, et al.
Publicado: (2019)

CD19(+) CD24(hi) CD38(hi) Regulatory B Cells and Memory B Cells in Periodontitis: Association with Pro-Inflammatory and Anti-Inflammatory Cytokines
por: Hetta, Helal F., et al.
Publicado: (2020)

Small round tumour cells (CD38, CD 79a positive) in the adrenal gland
por: Nigam, L.A., et al.
Publicado: (2017)

Redirection of CD4+ and CD8+ T lymphocytes via an anti-CD3 × anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells
por: Fan, Dongmei, et al.
Publicado: (2015)

High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites
por: Kraan, W, et al.
Publicado: (2013)

Expression of the B-Cell Receptor Component CD79a on Immature Myeloid Cells Contributes to Their Tumor Promoting Effects
por: Luger, Dror, et al.
Publicado: (2013)

Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma
por: Nagel, Daniel, et al.
Publicado: (2015)

CD79a promotes CNS-infiltration and leukemia engraftment in pediatric B-cell precursor acute lymphoblastic leukemia
por: Lenk, Lennart, et al.
Publicado: (2021)

B cell depletion with anti-CD20 mAb exacerbates anti-donor CD4(+) T cell responses in highly sensitized transplant recipients
por: Tanaka, Asuka, et al.
Publicado: (2021)

In vitro Anti‐tumor Activity of Anti‐c‐erbB‐2 × Anti‐CD3ɛ Bifunctional Monoclonal Antibody
por: Sugiyama, Yoshihiro, et al.
Publicado: (1992)

Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies
por: Dillman, R. O.
Publicado: (2006)

Integrin CD11b activation drives anti-tumor innate immunity
por: Schmid, Michael C., et al.
Publicado: (2018)

CD40-activated B cells induce anti-tumor immunity in vivo
por: Wennhold, Kerstin, et al.
Publicado: (2016)

Peripheral T-Cell Lymphoma with Aberrant Expression of CD19, CD20, and CD79a: Case Report and Literature Review
por: Matnani, Rahul G., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_b50625m3votouh4pintsnvpe38